ARTICLE INFO | ABSTRACT | |
ORIGINAL ARTICLE | Background: Sexual dysfunction is an important health problem which prevalence in patients with type 2 diabetes (T2D) is higher than other people. The aim of this study was to evaluate the effect of L-arginine oral supplementation on sexual function in men with T2D and mild-to-moderate erectile dysfunction (ED). Methods: Eighty men with T2D, suffering from mild-to-moderate erectile dysfunction participated in this double-blind clinical trial. They were randomly assigned in to two groups; receiving 5 g/day L-arginine (AG) or placebo group (PG) for 4 weeks. Sexual functions were recorded with international index of erectile function questionnaire at the beginning and end of the intervention. Total testosterone concentrations were measured too. Results: The total mean score of sexual function parameters significantly increased only in AG than PG (43.2 ± 6.2 vs. 39.4 ± 4.0, P = 0.003). Against PG, the mean of all parameters significantly improved in AG after intervention. Only the mean score of erectile function in AG had a significant increase compared to PG. Mean of other sexual activity scores between the two groups had no significant differences. The mean of testosterone concentration had a significant increase in both groups after the intervention, but the mean of changes was significantly higher in AG than in PG (1.91 μg/L vs. 0.53 μg/L, P = 0.004). Conclusions: The present trial showed that daily consumption of 5 g L-arginine for four weeks in T2D men with mild-to-moderate sexual dysfunction improved various parameters such as erectile function, sexual satisfaction, sexual desire, pleasure from sexual intercourse, and testosterone level. Keywords: Arginine supplementation; Diabetes mellitus; Erectile dysfunction; Sexual dysfunction; Testosterone |
|
Article history: Received: 25 Dec 2016 Revised: 15 Jan 2017 Accepted: 12 Mar 2017 |
||
IRCT code: 2015050322076N1 |
||
*Corresponding author: mozaffari.kh@gmail.com Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Shohaday Gomname BLV, Yazd, Iran. Postal code: 8915173160 Tel: +98 35 38209143 |
Table 1. Baseline characteristics | |||
Characteristics | Arginine group (n = 34) | Placebo group (n = 35) | P-valuea |
Age (y) | 51.58 ± 2.67 | 51.31 ± 2.65 | 0.99 |
Duration of disease (y) | 10.58 ± 3.87 | 10.42 ± 4.17 | 0.83 |
Height (cm) | 170.88 ± 7.57 | 171.40 ± 6.83 | 0.97 |
Weight (kg) | 76.91 ± 11.69 | 78.17 ± 12.21 | 0.79 |
BMI (kg/m2) | 26.29 ± 3.18 | 26.56 ± 3.68 | 0.14 |
Waist circumference (cm) | 99.32 ± 8.05 | 99.88 ± 9.53 | 0.11 |
Hip circumference (cm) | 94.94 ± 6.34 | 95.74 ± 5.96 | 0.45 |
Table 2. Mean (±SD) and confidence interval 95% of sexual function parameters between and within groups | ||||||
Sexual functions | Arginine group | Placebo group | P-valuea | |||
Mean ± SD | CI 95% | Mean ± SD | CI 95% | |||
Erectile function Before After |
16.32 ± 1.36 | 15.84-16.79 |
16.11 ± 1.30 | 15.66-16.56 |
0.51 |
|
18.67 ± 3.06 | 17.60-19.74 | 16.31 ± 1.92 | 15.65-16.97 | <0.001 | ||
P-valueb | <0.001 | 0.485 | ||||
Sexual satisfaction Before After |
5.08 ± 1.26 | 4.64-5.52 |
5.60 ± 1.06 | 5.23-5.96 |
0.07 |
|
5.58 ± 1.10 | 5.20-5.97 | 5.40 ± 1.06 | 5.03-5.76 | 0.47 | ||
P-value | 0.004 | 0.090 | ||||
Sexual desire Before After |
5.05 ± 0.91 | 4.03-5.37 |
5.37 ± 0.77 | 5.10-5.63 |
0.13 |
|
5.58 ± 0.98 | 5.24-5.93) | 5.22 ± 0.91 | 4.91-5.54 | 0.12 | ||
P-value | 0.018 | 0.392 | ||||
Pleasure from sexual intercourse Before After |
5.52 ± 1.46 |
5.01-6.03 |
6.22 ± 1.33 |
5.07-6.68 |
0.04 |
|
6.79 ± 1.66 | 6.21-7.37 | 6.25 ± 1.26 | 5.82-6.69 | 0.13 | ||
P-value | <0.001 | 0.879 | ||||
Marital satisfaction Before After |
6.64 ± 0.85 | 6.55-7.15 |
6.38 ± 0.75 | 6.03-6.54 |
0.15 |
|
6.85 ± 0.77 | 6.37-6.91 | 6.45 ± 0.75 | 5.90-6.61 | 0.81 | ||
P-value | 0.33 | 0.83 | ||||
Total score Before After |
38.8 ± 3.60 | 37.4-40.1 | 39.6 ± 3.09 | 38.5-40.2 | 0.35 | |
43.2 ± 6.02 | 41.1-45.3 | 39.4 ± 4.06 | 39.0-40.8 | 0.003 | ||
P-value | <0.001 | 0.787. | ||||
Total changes | 4.44 ± 5.7 | -0.14 ± 3.0 | <0.001 | |||
Table 3. Mean (± SD) and confidence interval 95% of testosterone concentration (μg/L) before and after intervention in both groups. | |||||
P-valuea | Placebo group (n = 35) | Arginine group (n = 34) | Periods | ||
CI 95% | Mean ± SD | CI 95% | Mean ± SD | ||
0.11 | 3.90-5.57 | 4.73 ± 2.42 | 3.67-4.96 | 4.32 ± 1.82 | Before |
0.82 | 4.52-6.01 | 5.27 ± 2.16 | 5.45-7.01 | 6.23 ± 2.23 | After |
0.004 | -0.14-1.23 | 0.53 ± 1.90 | 1.28-2.54 | 1.91 ± 1.80 | Changes |
0.001 | 0.001 | P-valueb |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |